Arsenic Trioxide During Consolidation for Patients with Previously Untreated Low/Intermediate Risk Acute Promyelocytic Leukaemia May Eliminate the Need for Maintenance Therapy

A total of 105 patients (age ≥ 18 years) with newly diagnosed low or intermediate risk acute promyelocytic leukaemia (APL) were treated with a standard induction and consolidation regimen including arsenic trioxide (ATO). Sixty-eight patients who were polymerase chain reaction (PCR) negative for PML...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Coutre, Steven E., Othus, Megan, Powell, Bayard, Willman, Cheryl L., Stock, Wendy, Paietta, Elisabeth, Levitan, Denise, Wetzler, Meir, Attar, Eyal C., Altman, Jessica K., Gore, Steven D., Maher, Tracy, Kopecky, Kenneth J., Tallman, Martin S., Larson, Richard A., Appelbaum, Frederick R.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4064464/
https://ncbi.nlm.nih.gov/pubmed/24528179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12775
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares